Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?
- PMID: 23738077
- PMCID: PMC3659516
- DOI: 10.1155/2013/905091
Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?
Abstract
Nanoparticle albumin bound paclitaxel (nab-paclitaxel) represents the first nanotechnology-based drug in cancer treatment. We discuss the development of this innovative compound and report the recent changing-practice results in breast and pancreatic cancer. A ground-breaking finding is the demonstration that nab-paclitaxel can not only enhance the activity and reduce the toxicity of chromophore-diluted compound, but also exert activity in diseases considered refractory to taxane-based treatment. This is the first clinical demonstration of major activity of nanotechnologically modified drugs in the treatment of human neoplasms.
Figures
References
-
- Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. Journal of the American Chemical Society. 1971;93(9):2325–2327. - PubMed
-
- Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. International Journal of Pharmaceutics. 2002;235(1-2):179–192. - PubMed
-
- Horwitz SB. Mechanism of action of taxol. Trends in Pharmacological Sciences. 1992;13(4):134–136. - PubMed
-
- Wall ME, Wani MC. Camptothecin and taxol: from discovery to clinic. Journal of Ethnopharmacology. 1996;51(1–3):239–254. - PubMed
-
- Correia JJ, Lobert S. Physiochemical aspects of tubulin-interacting antimitotic drugs. Current Pharmaceutical Design. 2001;7(13):1213–1228. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
